← Browse by Condition
Medical Condition

locally advanced unresectable hormone receptor positive breast carcinoma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for locally advanced unresectable hormone receptor positive breast carcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

  • Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
  • Phase 1–4 studies from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 2
1
Top Sponsors
University of Washington 1 trial

Recruiting Clinical Trials

NCT06179303 Phase 2
Recruiting

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Enrollment
60 pts
Location
United States
Sponsor
University of Washington
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology